Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
NSCLC MAGE-A3 immunotherapy development halted

NSCLC MAGE-A3 immunotherapy development halted

Disease-free survival is not prolonged with adjuvant MAGE-A3 immunotherapy in patients with surgically resected non-small-cell lung cancer, according to a placebo-controlled trial. [More]
Key method to test compounds for anti-cancer activity in cells flawed, study reveals

Key method to test compounds for anti-cancer activity in cells flawed, study reveals

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs. [More]
Stereotactic body radiation therapy for NSCLC patients may raise non-cancer mortality risk

Stereotactic body radiation therapy for NSCLC patients may raise non-cancer mortality risk

Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
Novel method may enable quick, easy exhaustive analysis of ORs responding to specific odorants

Novel method may enable quick, easy exhaustive analysis of ORs responding to specific odorants

A research group led by Osaka University and Panasonic Corporation developed a method for making a prompt, exhaustive isolation of olfactory receptors (ORs) responding to the odorant of interest. This achievement will enable quick and easy exhaustive analysis of ORs responding to specific odorants, which previously required a great deal of time and effort. These results may be applied to biosensors capable of highly detecting only desired odorants. [More]
Exposure to fine particulate matter in air can increase risk of cancer-specific mortality

Exposure to fine particulate matter in air can increase risk of cancer-specific mortality

In 2015, the International Agency for Research on Cancer (IARC) published a series of monographs on the evaluation of various carcinogenic risks. In a monograph on air pollution, the organization pointed out the difficulty of assessing the effects of pollution on multiple types of cancers, given their different etiologies, risk factors and variability in the composition of air pollutants in space and time. However, the IARC identified certain key components of air pollution, including particulates. [More]
Residential radon exposure may lead to hematologic cancer risk in women

Residential radon exposure may lead to hematologic cancer risk in women

A new report finds a statistically-significant, positive association between high levels of residential radon and the risk of hematologic cancer (lymphoma, myeloma, and leukemia) in women. The study is the first prospective, population-based study of residential radon exposure and hematologic cancer risk, leading the authors to caution that it requires replication to better understand the association and whether it truly differs by sex. It appears early online in Environmental Research. [More]
Clinical study shows watercress extract inhibits carcinogen activation in cigarette smokers

Clinical study shows watercress extract inhibits carcinogen activation in cigarette smokers

Watercress extract taken multiple times a day significantly inhibits the activation of a tobacco-derived carcinogen in cigarette smokers, researchers at the University of Pittsburgh Cancer Institute, partner with UPMC Cancer Center, demonstrated in a phase II clinical trial presented today at the American Association for Cancer Research Annual Meeting in New Orleans. [More]
Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
NanoString launches new nCounter Vantage assays that power 3D Biology experiments in cancer research

NanoString launches new nCounter Vantage assays that power 3D Biology experiments in cancer research

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the introduction of nCounter Vantage, a portfolio of assays that power 3D Biology™ experiments in cancer research, including immuno-oncology. [More]
Fujitsu develops portable breath sensor that can quickly measure concentration of gas components in people's breath

Fujitsu develops portable breath sensor that can quickly measure concentration of gas components in people's breath

Fujitsu Laboratories Ltd. today announced that it has developed a portable breath sensor that can extract and quickly measure the concentration of only specified gas components, such as ammonia, that are included at low concentrations in people's breath and are suggested to be correlated with lifestyle diseases. [More]
Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies. [More]
AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme. [More]
International scientists discuss new treatments for non small cell lung cancer

International scientists discuss new treatments for non small cell lung cancer

More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside. [More]
Pericardial window operation not effective in lung cancer cases, say researchers

Pericardial window operation not effective in lung cancer cases, say researchers

Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, or malignant pericardial effusion (MPE), surrounding the heart, is drained into the neighbouring chest cavity through a surgically placed tube, is commonly applied to patients diagnosed with cancer. [More]
Mouse-based study shows exercise decreases cancer incidence, slows tumor growth

Mouse-based study shows exercise decreases cancer incidence, slows tumor growth

When you're pounding along an icy pavement or sweating through a gym workout, you try to remind yourself of the many health benefits of exercise. Between gasps, you can say that a healthy, fit lifestyle helps prevents obesity, a worldwide problem of increasing magnitude that has been linked to cardiovascular disease and diabetes. [More]
Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment. [More]
Simple blood test rapidly detects key genetic mutations in non-small cell lung tumors

Simple blood test rapidly detects key genetic mutations in non-small cell lung tumors

A simple blood test can rapidly and accurately detect mutations in two key genes in non-small cell lung tumors, researchers at Dana-Farber Cancer Institute and other institutions report in a new study - demonstrating the test's potential as a clinical tool for identifying patients who can benefit from drugs targeting those mutations. [More]
Advertisement